KaydedilenlerDerginizi ekleyin

Dergiler / DAHUDER Medical Journal / 2023 / Cilt: 3 Sayı: 3

The relationship of serum bilirubin level with histopathological parameters in patients with nonalcoholic fatty liver disease

Ali KIRIK
Cemal Nuri ERCİN
Hasan GÜREL
Ali Fuat ÇİÇEK
Ali Cem YEKDEŞ
Sultan TÜREL
Serkan TAPAN
Teoman DOĞRU
Sayfa
91–96
Yayın Tarihi
2023-07-29
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The difference, shown in the other studies, may be the effect of other diseases related to MetS.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease and is known as a part of metabolic syndrome (MetS), and the role of bilirubin in the pathogenesis of NAFLD is unclear.
📊
Temel Bulgular & Veri:Results: The subjects in the nonalcoholic steatohepatitis (NASH) group had greater AST (p < 0.001) and ALT (p < 0.001) levels than the non-NASH group.
💡
Sonuç & Katkı:The difference, shown in the other studies, may be the effect of other diseases related to MetS.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:NAFLD · NASH · fibrosis

Abstract

Objectives: Non-alcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease and is known as a part of metabolic syndrome (MetS), and the role of bilirubin in the pathogenesis of NAFLD is unclear. This study aimed to evaluate the relationship between bilirubin levels and histopathological findings in patients with NAFLD having no confounding factors such as morbid obesity, diabetes mellitus (DM), and hypertension. Methods: A retrospective analysis of clinical and laboratory data of patients with biopsy-proven NAFLD was performed. The relationship between the bilirubin levels and histopathologic findings was evaluated. Results: The subjects in the nonalcoholic steatohepatitis (NASH) group had greater AST (p < 0.001) and ALT (p < 0.001) levels than the non-NASH group. We found no difference between NASH and non-NASH groups regarding bilirubin levels. The levels of AST (p = 0.001), ALT (p = 0.011), insulin (p = 0.029), and HOMA-IR index (p = 0.027) were higher in fibrosis group comparing non-fibrosis group. However, bilirubin levels were not different comparing the fibrosis and non-fibrosis group. We couldn’t find any relation between bilirubin levels and other parameters in correlation analysis. Conclusion: We couldn’t find any relation between the bilirubin levels and histopathological findings of the patient with NAFLD having no confounding factors such as morbid obesity, DM, and hypertension. The difference, shown in the other studies, may be the effect of other diseases related to MetS.

🔖

Bu Makaleye Atıf Yap

KIRIK, A., ERCİN, C. N., GÜREL, H., ÇİÇEK, A. F., YEKDEŞ, A. C., TÜREL, S., TAPAN, S., DOĞRU, T. (2023). The relationship of serum bilirubin level with histopathological parameters in patients with nonalcoholic fatty liver disease. DAHUDER Medical Journal, Cilt: 3 Sayı: 3, 91–96. https://ajindex.com/articles/958174

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (8)

  1. Fang YL, Chen H, Wang CL, Liang L. Pathogenesis of non-alcoholic fatty liver disease in chil-dren and adolescence: From "two hit theory" to "multiple hit model". World J Gastroenterol. 2018;24(27):2974-2983.
  2. Sonmez A, Dogru T, Ercin CN, Genc H, Celebi G, Gurel H, et al. Betatrophin Levels Are Re-lated to the Early Histological Findings in Nonalcoholic Fatty Liver Disease. Metabolites. 2021;11(7):425. Oni ET, Agatston AS, Blaha MJ, Fialkow J, Cury R, Sposito A, et al. A systematic review: burden and severity of subclinica lcardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis 2013; 230(2):258-267.
  3. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fat-ty liver disease. N Engl J Med. 2010; 363(14):1341-1350.
  4. Dogru T, Kirik A, Gurel H, Rizvi AA, Rizzo M, Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int J Mol Sci. 2021;22(12):6627. Pacifico L, Chiesa C, Anania C, Merulis AD, Osborn JF, Romaggioli S, et al. Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol 2014; 20(27):9055–9071. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64(6):1388-1402.
  5. Erlinger S, Arias IM, Dhumeaux D. Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 2014; 146(7):1625-1638.
  6. DiNicolantonio JJ, McCarty MF, O'Keefe JH. Antioxidant bilirubin works in multiple ways to reduce risk for obesity and its health complications. Open Heart. 2018;5(2):e000914. Neuzil J, Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for alpha-tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation. J Biol Chem 1994; 269(24):16712-16719.
  7. Ndisang JF, Jadhav A. Up-regulating the hemeoxygenase system enhances insulin sensitivity and improves glucose metabolism in insulin-resistant diabetes in Goto-Kakizakirats. Endocrinol 2009; 150(6):2627-2636.
  8. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, et al. Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009; 203(2):563-568. Jai